Challenges in Managing Persistent COVID-19 in Immunocompromised Patients

Strategic Insights -

A new report highlights the difficulties in treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in patients with hematological malignancies who are immunocompromised due to their underlying disease or medical treatment. Researchers from the Department of Respirology in Japan present a case study of an 84-year-old man with stage 3 diffuse large B-cell lymphoma who developed persistent severe SARS-CoV-2 infection despite receiving multiple doses of COVID-19 mRNA vaccine and remdesivir.

Key Takeaways:

  • The patient was treated with a combination of remdesivir, sotrovimab, and nirmatrelvir/ritonavir, and eventually recovered clinically, highlighting the challenges in managing persistent SARS-CoV-2 infection in immunocompromised patients.
  • The case study suggests that combined treatment with antivirals and monoclonal antibodies may be an effective strategy in managing persistent SARS-CoV-2 infection.
  • The patient's condition was diagnosed using SARS-CoV-2 polymerase chain reaction and antigen tests, which were eventually turned negative, and he was discharged after 28 days of hospitalization.
  • The study discusses the limited treatment options for immunocompromised patients with hematological malignancies who develop persistent SARS-CoV-2 infection.
  • The authors emphasize the importance of considering individual patient characteristics and circumstances when determining treatment approaches for COVID-19.
  • The study suggests that further research is needed to develop effective treatments for immunocompromised patients with persistent SARS-CoV-2 infection.

Statistics:

  • The patient was 84 years old and had stage 3 diffuse large B-cell lymphoma.
  • He received seven doses of COVID-19 mRNA vaccine and was treated with remdesivir, sotrovimab, and nirmatrelvir/ritonavir.
  • He was hospitalized for 28 days, during which time he received multiple treatments for his SARS-CoV-2 infection.
  • The SARS-CoV-2 polymerase chain reaction and antigen tests were eventually turned negative.
  • The patient recovered clinically, but the study highlights the challenges and complexities of managing persistent SARS-CoV-2 infection in immunocompromised patients.

Sources:

  • Case Report: Persistent COVID-19 in a fully vaccinated Japanese man being treated with rituximab and epcoritamab for diffuse large B-cell lymphoma. Frontiers in Medicine, 2025,12.
  • NewsRx. New Remdesivir Research Has Been Reported by Researchers at Department of Respirology (Case Report: Persistent COVID-19 in a fully vaccinated Japanese man being treated with rituximab and epcoritamab for diffuse large B-cell lymphoma). Hematology Week. May 12, 2025; p 195.